Tevimbra Injection, Solution, Concentrate
NDC Package 72579-125-00

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Tevimbra (tislelizumab-jsgr) injection is tEVIMBRA (tislelizumab-jsgr), as a single agent, is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. This formulation utilizes a injection, solution, concentrate delivery system. Marketed by Beone Medicines Usa, Inc., this product is identified by NDC 72579-125 and is authorized under FDA application BLA761232.

Identification & Billing

NDC Package Code
72579-125-00
Package Description
1 VIAL, GLASS in 1 CARTON / 15 mL in 1 VIAL, GLASS
Product Code
72579-125
11-Digit Billing Format
72579012500

Clinical Specifications

Proprietary Name
Tevimbra
Non-Proprietary Name
Tislelizumab-jsgr
Substance Name
Tislelizumab
Dosage Form
Injection, Solution, Concentrate - A sterile preparation for parenteral use which, upon the addition of suitable solvents, yields a solution conforming in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
TISLELIZUMAB 10 mg/mL
Pharmacologic Class
Usage Information
TEVIMBRA (tislelizumab-jsgr), as a single agent, is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.

Regulatory & Marketing

Labeler Name
Beone Medicines Usa, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761232
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
07-13-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72579-125-00 identifies a specific commercial package of 1 vial, glass in 1 carton / 15 ml in 1 vial, glass of Tevimbra, a human prescription drug labeled by Beone Medicines Usa, Inc.. This injection, solution, concentrate is formulated for intravenous use and contains tislelizumab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Beone Medicines Usa, Inc. on July 13, 2026. The current certification is valid through December 31, 2027.

How is this Beone Medicines Usa, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72579012500. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72579-125-00
11-Digit CMS (5-4-2)
72579-0125-00

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.